Table 2.

Adverse events related to TILT-123 therapy as judged and reported by the investigator, stratified by grade, cohort, and unique patients with reported adverse event.^a

Event type							Cohort	Cohort	Cohort	Cohort	Cohort	Cohort
	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5	Total	1 (2 patients)	2 (4 patients)	3 (3 patients)	4 (3 patients)	5 (3 patients)	6 (5 patients)	Unique patients
Infection-likesymptoms
Fever	14	4	0	0	0	18	0	1	6	2	0	9	9/20
Chills	13	1	0	0	0	14	0	3	1	2	2	6	7/20
Subfebrile body temperature	3	0	0	0	0	3	0	0	1	2	0	0	2/20
Flu-like symptoms	1	0	1	0	0	2	0	0	0	1	0	1	2/20
General
Fatigue	5	3	1	0	0	9	0	2	1	2	2	2	7/20
Tiredness	3	3	0	0	0	6	1	0	1	0	4	0	3/20
Nausea	1	1	0	0	0	2	0	0	0	0	0	2	2/20
Dry mouth	1	0	0	0	0	1	0	0	0	1	0	0	1/20
Headache	1	0	0	0	0	1	0	0	0	0	1	0	1/20
Hot flushes	1	0	0	0	0	1	0	0	0	1	0	0	1/20
Tinnitus	1	0	0	0	0	1	1	0	0	0	0	0	1/20
Hematological
Neutrophil count decreased	0	1	4	1	0	6	0	0	1	5	0	0	2/20
Leukocyte count decreased	0	4	1	0	0	5	0	0	1	4	0	0	2/20
Platelet count decreased	1	1	0	1	0	3	0	0	0	1	2	0	2/20
Lymphocyte count decreased	0	0	1	1	0	2	0	0	0	0	1	1	2/20
Renal
Creatinine increased	1	1	0	0	0	2	0	0	0	1	0	1	2/20
Gastrointestinal Diarrhea	1	1	0	0	0	2	0	1	0	0	0	1	2/20
Loss of appetite	2	0	0	0	0	2	0	0	0	0	1	1	2/20
Vomiting	2	0	0	0	0	2	0	0	0	0	0	2	2/20
Cardiovascular
Edema in feet	1	0	0	0	0	1	1	0	0	0	0	0	1/20
Musculoskeletal
Muscle pain	4	1	0	0	0	5	0	0	0	0	4	1	3/20
Joint pain	3	1	0	0	0	4	0	0	0	1	0	3	2/20
Pain in extremities	2	0	0	0	0	2	0	1	0	1	0	0	2/20
Muscle cramps	1	0	0	0	0	1	0	0	0	0	1	0	1/20
Worsening of pain in left knee	0	1	0	0	0	1	0	0	0	1	0	0	1/20
Immunological
Cytokine release syndrome	1	1	0	0	0	2	0	0	0	1	0	1	2/20
Local lesion symptoms
Pain in tumor	4	4	0	0	0	8	0	0	0	0	7	1	3/20
Infection in tumor	0	1	0	0	0	1	0	0	0	0	1	0	1/20
Itching in tumor	1	0	0	0	0	1	0	0	0	0	1	0	1/20
Swelling of metastases	1	0	0	0	0	1	1	0	0	0	0	0	1/20
Total	68	29	8	3	0	109	4	8	12	26	27	33	18/20
Total per patient	3.4	1.5	0.4	0.2	0	5.5	2	2	4	8.7	9	6.6

^aEvents reported as of November 11, 2023.